Kilitch Drugs Standalone September 2024 Net Sales at Rs 45.35 crore, up 43.63 percent Y-o-Y - Moneycontrol
| KILITCH Stock | 310.05 3.95 1.29% |
Under 51% of Kilitch Drugs' traders are presently thinking to get in. The analysis of overall sentiment of trading Kilitch Drugs Limited stock suggests that some investors are interested at this time. Kilitch Drugs' investing sentiment shows overall attitude of investors towards Kilitch Drugs Limited.
Kilitch |
Kilitch Drugs Standalone September 2024 Net Sales at Rs 45.35 crore, up 43.63 percent Y-o-Y Moneycontrol
Read at news.google.com
 |
Kilitch Drugs Fundamental Analysis
We analyze Kilitch Drugs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kilitch Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kilitch Drugs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Kilitch Drugs is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Kilitch Drugs Limited Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kilitch Drugs stock to make a market-neutral strategy. Peer analysis of Kilitch Drugs could also be used in its relative valuation, which is a method of valuing Kilitch Drugs by comparing valuation metrics with similar companies.
Peers
Kilitch Drugs Related Equities
| ARVIND | Arvind | 3.34 | ||||
| COSMOFIRST | COSMO FIRST | 2.19 | ||||
| PARAGMILK | Parag Milk | 2.10 | ||||
| RICOAUTO | Rico Auto | 1.78 | ||||
| LEMONTREE | Lemon Tree | 1.43 | ||||
| KINGFA | Kingfa Science | 0.88 | ||||
| CHEMCON | Chemcon Speciality | 0.32 | ||||
| HEUBACHIND | Heubach Colorants | 0.16 | ||||
| TBZ | Tribhovandas Bhimji | 0.96 | ||||
| GATECHDVR | GACM Technologies | 5.56 |
Complementary Tools for Kilitch Stock analysis
When running Kilitch Drugs' price analysis, check to measure Kilitch Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kilitch Drugs is operating at the current time. Most of Kilitch Drugs' value examination focuses on studying past and present price action to predict the probability of Kilitch Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kilitch Drugs' price. Additionally, you may evaluate how the addition of Kilitch Drugs to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |